BLEEDING DURING THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - MECHANISMS AND MANAGEMENT

被引：95

作者：

SANE, DC

CALIFF, RM

TOPOL, EJ

STUMP, DC

MARK, DB

GREENBERG, CS

机构：

[1] UNIV MICHIGAN, ANN ARBOR, MI 48109 USA

[2] UNIV VERMONT, BURLINGTON, VT USA

来源：

关键词：

D O I：

10.7326/0003-4819-111-12-1010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1010 / 1022

页数：13

共 100 条

[1] ABRAMOWICZ M, 1987, MED LETT DRUGS THER, V29, P89
[2] ADDONIZIO VP, 1980, CIRCULATION, V62, P326
[3] ADELMAN B, 1986, BLOOD, V68, P1280
[4] ADELMAN B, 1985, BLOOD, V65, P32
[5] [Anonymous], 1988, LANCET, V2, P349
[6] THE CLINICAL-SIGNIFICANCE OF FIBRINOGEN DEGRADATION PRODUCTS
BICK, RL
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1982, 8 (04) : 302 - 330
[7] TYPE AND SCREEN - SAFE ALTERNATIVE AND SUPPLEMENT IN SELECTED SURGICAL PROCEDURES
BORAL, LI
HENRY, JB
[J]. TRANSFUSION, 1977, 17 (02) : 163 - 168
[8] BORCHGREVINK C, 1961, ACTA MED SCAND, V170, P375
[9] TRANSFUSION OF PLASMA COMPONENTS
BRAUNSTEIN, AH
OBERMAN, HA
[J]. TRANSFUSION, 1984, 24 (04) : 281 - 286
[10] BROGDEN RN, 1973, DRUGS, V5, P57